{
    "nct_id": "NCT03397264",
    "official_title": "Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema",
    "inclusion_criteria": "* History of diabetic macular edema (DME) ≤ 2 year\n* Persistent DME despite prior intravitreal anti-VEGF-A therapy with a sub-optimal response\n* Three or more prior anti-VEGF-A therapy intravitreal injections\n* EDTRS BCVA score ≤ 73 and ≥ 24 letters\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Ocular disorders or ocular treatments which may interfere with assessment of visual acuity, assessment of toxicity, or fundus photography in the Study Eye\n* HbA1c ≥ 12% and/or recent signs of uncontrolled diabetes\n* Any clinically significant disorder or condition or disease (e.g. cardiovascular, renal conditions) that would make the participant unsuitable for the study",
    "miscellaneous_criteria": ""
}